Feasibility and Acceptability of Maternal Choline Supplementation in Heavy Drinking Pregnant Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Sandra W. Jacobson, R. Colin Carter, Christopher D. Molteno, Ernesta M. Meintjes, Marianne S. Senekal, Nadine M. Lindinger, Neil C. Dodge, Steven H. Zeisel, Christopher P. Duggan, and Joseph L. Jacobson

Background: Choline, an essential nutrient, serves as a methyl-group donor for DNA methylation and is a constituent of the neurotransmitter acetylcholine and a precursor to major components of cell membranes. Findings from animal studies suggest that choline supplementation during pregnancy can mitigate adverse effects of prenatal alcohol exposure on growth and neuropsychological function. We conducted a randomized, double-blind exploratory trial to examine feasibility and acceptability of a choline supplementation intervention during pregnancy.

Methods: Seventy heavy drinkers, recruited in mid-pregnancy, were randomly assigned to receive a daily oral dose of 2 g of choline or a placebo from time of enrollment until delivery. Each dose consisted of an individually wrapped packet of powder that, when mixed with water, produced a sweet tasting grape-flavored drink. Adherence was assessed by collecting used and unused drink packets on a monthly basis and tabulating the number used. Side effects were assessed in monthly interviews. Blood samples obtained at enrollment and at 4 and 12 weeks after randomization were assayed for plasma choline concentration.

Results: Adherence was good-to-excellent (median doses taken = 74.0%; interquartile range = 53.9 to 88.7%) and was not related to a range of sociodemographic characteristics or to alcohol consumption ascertained using a timeline follow-back interview. By 4 weeks, plasma choline concentrations were significantly higher in the choline supplementation than the placebo arm, and this group difference continued to be evident at 12 weeks. The only side effect was a small increase in nausea/dyspepsia. No effects were seen for diarrhea, vomiting, muscle stiffness, blood pressure, or body odor changes.

Conclusions: This study demonstrated that a choline supplementation program with very heavy drinkers during pregnancy is feasible even among highly disadvantaged, poorly educated women. The broad acceptability of this intervention is indicated by our finding that adherence was not related to maternal education, intellectual function, depression, nutritional status, or alcohol use.

Key Words: Fetal Alcohol Spectrum Disorders, Prenatal Alcohol Exposure, Fetal Alcohol Syndrome, Maternal Choline Supplementation, Feasibility, Adherence.

Descriptive studies spanning 4 decades have documented poor fetal growth, distinctive craniofacial dysmorphology, and a broad range of cognitive and behavioral deficits in infants and children with prenatal alcohol exposure (PAE; e.g., Carter et al., 2016; Coles et al., 1997; Day et al., 2002; Jacobson et al., 1994, 2004, 2011; Kable and Coles, 2004; Mattson et al., 2011; Streissguth et al., 1994). Although the adverse effects associated with alcohol...
exposure are well known and numerous psychosocial interventions have been attempted, alcohol consumption during pregnancy continues to pose a major health risk. There is, therefore, a growing interest in new approaches, such as pharmacological and nutritional interventions, that may be more effective. Among these, maternal choline supplementation during pregnancy seems particularly promising.

Choline is an essential nutrient that is a constituent of the neurotransmitter acetylcholine and a precursor to phosphatidylcholine and sphingomyelin, which are major components of cell membranes and play an important role in cell membrane integrity, transmembrane signaling, and triglyceride turnover from the liver and blood (Zeisel and Niculescu, 2006). In addition, it serves as a methyl-group donor needed for homocysteine metabolism and DNA methylation, a critical mechanism in epigenetic processes that have been implicated in alcohol teratogenesis.

Choline is derived from dietary intake, principally eggs, liver, wheat germ, and milk. In addition, it can be derived from endogenous synthesis, catalyzed by the enzyme phosphatidylethanolamine-N-methyltransferase (PEMT; Ressegui et al., 2007). PEMT is induced by estrogen and is thus a significant source of choline only in premenopausal women. Estrogen induction of PEMT helps women meet some of the increased choline demands during pregnancy when transport of choline to the fetus depletes maternal stores (McMahon and Farrell, 1985; Zeisel et al., 1995). Presence of a common single nucleotide polymorphism (SNP) variant (rs12325817) in the promoter region of the PEMT gene confers markedly greater risk of choline deficiency (da Costa et al., 2006; Kohlmeier et al., 2005). In 1 study of premenopausal women with a low choline diet, 80% of women with 2 variant alleles and 43% of those with 1 allele developed choline deficiency-induced organ dysfunction, compared with 13% of women without the SNP variant (Fischer et al., 2010). Thus, in women of child-bearing age, this variant prevents estrogen induction of the PEMT gene, reducing the ability to synthesize choline needed to sustain normal fetal development.

Findings from animal studies suggest that supplementation with choline during pregnancy can mitigate the effects of PAE on growth and development. Choline supplementation in rats during the equivalent of the third trimester in humans reduces the impact of fetal alcohol exposure on brain and body weight at birth (Thomas et al., 2009) and a range of cognitive and behavioral outcomes, including eyelid conditioning (Thomas and Tran, 2012), hyperactivity (Idrus et al., 2017; Thomas et al., 2004a, 2007), spatial learning (Thomas et al., 2007), working memory (Thomas et al., 2000), reversal learning (Thomas et al., 2004a), and trace fear conditioning (Wagner and Hunt, 2006), although not motor balance and coordination (Thomas et al., 2004b; but cf. mouse study by Bearer et al., 2015). These changes persist even after choline treatment was completed, indicating long-lasting effects on central nervous system organization and development. Although choline was administered in most of these studies during the equivalent of the third trimester of pregnancy, treatment with this micronutrient is even more effective when administered earlier in pregnancy (Meck et al., 1989; Ryan et al., 2008; Thomas et al., 2009).

We conducted a randomized, double-blind, placebo-controlled exploratory trial to assess the feasibility, acceptability, and efficacy of maternal choline supplementation in a sample of socioeconomically disadvantaged heavy drinking pregnant women in Cape Town, South Africa. This intervention was based on the premise that infants would show improvement if supplementation were initiated early and at high doses during pregnancy. In this article, we present findings relating to the feasibility and acceptability of the trial; findings relating to efficacy are presented in a companion paper (Jacobson et al., 2018). The analyses presented in this article were performed: (i) to determine the degree to which women in this community would adhere to the supplementation protocol; (ii) to examine the degree to which adherence would be related to level of maternal alcohol consumption, socioeconomic status (SES), intellectual function, and other sociodemographic characteristics; (iii) to determine whether choline supplementation at this dose and frequency would lead to an increase in maternal plasma choline levels; (iv) to identify any adverse side effects that may be associated with choline supplementation; and (v) to determine the prevalence in this community of 2 factors believed to enhance the efficacy of a choline supplementation intervention—inadequate choline intake in the diet and the presence of the PEMT SNP rs12325817.

MATERIALS AND METHODS

Trial Design

Heavy drinking pregnant women initiating antenatal care by the 23rd week of gestation were randomly assigned to either choline supplementation or placebo using a randomization list (variable blocks of 2 and 4 subjects with 1:1 allocation ratio) by a biostatistician not otherwise involved in the trial, using a computer-generated schema (see Fig. 1). All participants, investigators, and research staff remained blind to the treatment group assignment throughout the trial. The randomization list was accessible only by R. Anzaldi, RPh, a senior research pharmacist at Boston Children’s Hospital who coordinated the randomization and labeling of the treatment course regimens, and W. Smythe, PhD, BPharm, Division of Clinical Pharmacology, University of Cape Town (UCT).

Participants

Heavy drinking pregnant women were recruited from the Cape Coloured (mixed ancestry) community in Cape Town, South Africa. This population, descendants of white European, Malaysian, Khoi-San, and black African ancestors, historically comprised the large majority of workers in the wine-producing region of the Western Cape. The high prevalence of heavy drinking during pregnancy and fetal alcohol syndrome (FAS) in this community (Croxford and Wiljoen, 1999; May et al., 2013) is a consequence of poor psychosocial circumstances and the traditional dop system, in which farm laborers were paid, in part, with wine. Although the dop system has been outlawed and despite widely disseminated public health advisories at antenatal clinics and psychosocial community-based interventions, heavy alcohol consumption and weekend binge drinking...
persist in urban and rural Cape Coloured communities (May et al., 2013).

Human subjects approval was obtained from the Wayne State University, UCT Faculty of Health Sciences, and Columbia University Medical Center Institutional Review Boards and the South African Medicines Control Council. Informed consent was obtained from each mother and the father, if available. An independent data safety monitoring board, comprised of a developmental psychologist, obstetrician, neonatologist, and statistician, met with SWJ, CDM, RCC, and JLJ via telephone prior to initiation of the trial to review the research plan and every 9 months thereafter to review the progress of the trial and any study-related adverse events.

**Alcohol Ascertainment and Study Recruitment**

Participants were screened initially by 1 of our research nurses at 2 neighborhood midwife obstetrics units (MOUs) that serve economically disadvantaged, primarily Cape Coloured neighborhoods. We adapted this interview to include information about the type of beverage consumed, container size (including pictures of different containers, bottles, cans, glass size), and sharing (size of container divided by number of women drinking together) to reflect how pregnant women in this community frequently drink (Jacobson et al., 2008, 2017). The estimates of alcohol consumption during pregnancy derived from this interview have been validated in relation to fatty acid ethyl esters, biologically stable metabolites of alcohol that are deposited in meconium (Bearer et al., 2003), and infant (Jacobson et al., 2002) and child outcomes (e.g., Carter et al., 2016; Lewis et al., 2015; Lindinger et al., 2016; Meintjes et al., 2014). All interviews were conducted by CDM in Afrikaans or English, depending on the mother’s preference.

In the initial TLFB interview, each woman was asked about her drinking on a day-by-day basis during a typical 2-week period at

---

**Fig. 1.** Flow diagram of the progression of participants through the trial.
time of conception. She was then asked whether her drinking had changed since conception; if so, when the change occurred and how much she drank on a day-by-day basis during the past 2 weeks. Volume was recorded for each type of beverage consumed each day and converted to oz absolute alcohol (AA; 1 oz AA ≈ 2 standard drinks) using the following weights that reflect potency of AA in Cape Town: liquor—0.4, beer—0.05, wine—0.12, cider—0.06. Heavy drinking was defined as an average of at least 1.0 oz AA per day or at least 1 incident of binge drinking (4 or more standard drinks/occasion). Heavy drinkers were invited to participate in the trial and randomly assigned to either the choline supplementation (n = 35) or placebo arm (n = 35). At time of recruitment and at each antenatal visit to our laboratory, CDM advised the mother that stopping or reducing her drinking would be beneficial for her and her baby and offered referral for treatment.

Maternal exclusionary criteria were age <18 years; HIV infection; multiple gestation pregnancy; pharmacologic treatment for a serious preexisting medical condition (e.g., diabetes, hypertension, epilepsy, or cardiac problems); use of methamphetamine, a popular drug at the time of recruitment; or plans to move from the area before study completion. Infant exclusionary criteria were major chromosomal anomalies, neural tube defects, seizures, very low birthweight (<1,500 g), and gestational age (GA) <32 weeks.

**Treatment Regimen**

Participants received a daily oral dose of either 2 g of choline or a placebo from time of enrollment until delivery. The choline dose was chosen in consultation with SHZ to maximize potential benefits, based on findings from pregnancy studies (e.g., Cheatham et al., 2012; Gossell-Williams et al., 2005), while being well within the parameters for safety determined by the Institute of Medicine (IOM) Food and Nutrition Board (FNB; Institute of Medicine, 2006). The FNB has identified the lowest observed-adverse effect level (LOAEL) for choline as 7.5 g/d based on data reporting “slight hypotension” at that dose (Boyd et al., 1977). To derive the tolerable upper intake level (UL) of choline, the FNB applied an uncertainty factor of 2 to the LOAEL to obtain a UL of 3.75 g/d, which was rounded down to 3.5 g/d. With respect to side effects, subjects treated with very high doses of choline (10 to 16 g/d) exhibited fishy body odor, vomiting, salivation, sweating, and gastrointestinal effects (LSRO/FASEB, 1981). Mild hypotension, the only side effect seen in patients receiving 7.5 g/d, was not seen at 4 g/d (Boyd et al., 1977).

To assess dietary choline intake, we developed a semi-quantitative, choline-indicated food frequency questionnaire (QFFQ), which focuses on choline-rich foods in the South African diet (Carter RCC, Jacobson SW, Booley S, Najaar B, Dodge NC, Bechard LJ, Meintjes EM, Molteno CD, Duggan CP, Jacobson JL, Senekal MS, under review), and administered it to a pilot sample of 24 women of child-bearing age from the Cape Coloured community. For a large majority (83.3%), average choline intake was below the 0.73 to 1.04 g/d average range reported in the United States, and none consumed >1.5 g/d. To determine the choline dose for the trial, we subtracted the highest level of daily dietary choline intake seen in this pilot sample (1,040 mg/d) from the UL (3.5 to 1.04 g) and rounded this dose (2.46 g) down to 2 g to ensure safety. To ensure that with supplementation and regular dietary intake, no participant would exceed the UL of 3.5 g/d, we administered the QFFQ to each participant prior to initiation of and twice during the trial. Each woman was instructed to take 2 daily doses (1 in the morning, 1 in the evening) from time of enrollment until delivery. Each choline supplement consisted of 1.25 g choline bitartrate, which contained 1 g of bioavailable choline cation (Bulchem, New Hampton, NY). Each dose consisted of an individually wrapped packet of powder that, when mixed with 8 oz of water, resulted in a sweet tasting, slightly fizzy, grape-flavored drink. The choline supplement and placebo were indistinguishable in terms of taste, smell, and appearance. When the participant was given the packets, CDM cautioned her that taking the drink mix would not make it safe to drink alcohol during pregnancy.

**Stability.** Choline content in the packets was analyzed on an AccuTest® 6 + 2 drugs of abuse panel test (DTA Pty Ltd, Cape Town). Choline oxidase as the immobilized enzyme (YSI Biochemistry Analyzer (https://www.ysi.com/ysi-2950-biochemistry-analyzer)), using choline oxidase as the immobilized enzyme (Fig. 2). On average, choline content was within 2.3% of target (median = 1.1%; range = 0.0 to 6.0%) and remained stable over the course of the study duration. Percent deviation from target dose was unrelated to time since supplement manufacture, r = −0.11.

**Randomization and Treatment Phase Monitoring**

At the initiation of the trial, CDM assigned the mother an ID number from the randomization list that determined whether she was in the treatment or placebo arm. She was given a box with a 1-month supply of drink packets and asked to return each of the used empty packets to the box. Our research nurse instructed her on how to mix the powder with water and visited her at home within 1 to 2 days to check how she was doing with taking the supplement and again 1 week later to interview her about possible side effects. At the end of each month, the nurse collected the box containing all the used and unused packets, replacing it with a new 1-month supply. Of the 329 boxes that were distributed, 8 (2.4%) were lost by the study subject. To assess adherence to the regimen, number of drink packets used during each month was tabulated in our laboratory by the nurse and independently by NML. Adherence was assessed as the percentage of drink packets distributed to the participant during the course of the trial that were empty when the participant’s boxes were returned to our staff. At each monthly visit, the nurse also discussed the participant’s adherence to treatment, identified potential barriers to adherence, recommended solutions to these problems, and recorded possible adverse events. Although the women liked the taste of the fizzy grape drink, a few reported nausea or discomfort and found that it was better tolerated when not consumed on an empty stomach. We therefore provided each participant with a monthly supply of crackers to eat with the grape drink.

**Maternal Assessments During the Trial**

Participants were transported in our research van to our UCT laboratory for 2 additional prenatal visits—at 4 and 12 weeks after randomization. Mothers were given breakfast and a snack during the morning at all laboratory visits. At the end of each visit, the mother received a small monetary compensation.

The TLFB was re-administered at the 4- and 12-week visits, and data from the 3 interviews were averaged to provide 3 continuous measures of drinking during pregnancy: average oz AA consumed per day, oz AA/drinking day (dose/occasion) and frequency (d/wk). Alcohol abuse and/or dependence was diagnosed based on DSM-IV criteria using the Structured Clinical Interview for DSM-IV (First et al., 2002). Demographic and background data were also collected, including weeks gestation at randomization, maternal age, parity, gravidity, SES (Hollingshead, 2011), education (years), marital status (married/unmarried), verbal (Peabody Picture Vocabulary Test) and nonverbal (Raven Progressive Matrices) intellectual function, depression (Beck Depression Inventory), and stressful life events (Holmes and Rahe, 1967; Yumoto et al., 2008).

Mothers were also asked about their drug use during pregnancy at each prenatal visit. Marijuana ("dagga"), cocaine, heroin, methaqualone ("mandrax"), and methamphetamine ("tik") were measured in d/wk, smoking as cigarettes per day. To assess the validity of the maternal reports of drug use, urine samples were collected from the last 30 women enrolled in the trial. Samples were tested using the AccuTest® 6 + 2 drugs of abuse panel test.
FASD PRENATAL CHOLINE RCT FEASIBILITY

1319

Fig. 2. Stability of choline cation in choline-fortified grape beverage sachet/packet.

Town, South Africa), an immunochemical assay that detects metabolites of drugs commonly used in this community (amphetamine, cocaine, methaqualone, methamphetamine, opiates, and marijuana [THC]), as well as pH and creatinine to test for sample adulteration. No woman refused urine drug testing.

Maternal weight during pregnancy was measured on a digital scale with 100 g precision and height with a stadiometer. GA was assessed based on ultrasound for 85.7% of the participants; for the others, it was based on last menstrual period. Dietary choline intake was assessed using our QFFQ prior to initiation and twice during the trial (Carter RCC, Jacobson SW, Booley S, Najaar B, Dodge NC, Bechard LJ, Meintjes EM, Molteno CD, Duggan CP, Jacobson JL, Senekal MS, under review). In addition, a registered dietitian or a research assistant with extensive training in dietary interviewing administered a multiple-pass 24-hour dietary recall interview to assess nutritional status (Carter et al., 2017). The 24-hour recall interview was quantified by L. Bechard, a research dietitian at Boston Children’s Hospital, using FoodFinder3, a dietary analysis software program developed by the South African Medical Research Council (Tygerberg, South Africa) to assess energy and nutrient content in the South African diet.

The participant was interviewed monthly either at her home or our UCT laboratory regarding any side effects, including diarrhea, nausea, vomiting, or muscle stiffness. She was also asked about any side effects and other medical problems that developed during the trial. Vomiting, fever, cough, diarrhea, body rash, and change in appetite in the preceding month, and urinalysis. Screening laboratories routinely include HIV antibody, complete blood count, and glucose. Folate and iron supplements are provided by the clinic. A glucose tolerance test is performed if there is a history of diabetes or an elevated random glucose. Women are strongly encouraged to limit or abstain from drinking during pregnancy to promote the health of the baby.

Data Analysis

Statistical analyses were performed using SPSS software (v.22; IBM, Armonk, NY), except for mixed model repeated measures regression, which was performed using SAS v.9.3 software (SAS Institute Inc., Cary, NC). All variables were checked for normality of distribution. Success of the randomization was assessed by comparing the choline treatment and placebo groups using t-tests and \( \chi^2 \) analysis on alcohol and drug use during pregnancy and a range of sociodemographic variables. t-Tests were used to compare adherence (% empty drink packets returned) between groups, and Pearson \( r \) was used to examine the relation of adherence to the alcohol consumption and background measures. The validity of our assessments of adherence based on packet counts was assessed in relation to change in maternal plasma choline level during the course of the trial using mixed model repeated measures regression. t-Tests and \( \chi^2 \) were used to compare the 2 groups in terms of maternal reported side effects and other medical problems that developed during the trial. \( \chi^2 \) was used to compare the groups on prevalence of

\[ \text{SBP} = \frac{1}{3}(\text{SBP} + 2 \times \text{DBP}) \]

\[ \text{MAP} = \text{DBP} + \frac{1}{3}(2 \times \text{SBP} + \text{DBP}) \]

\[ \text{Choline cation content, } \text{g dilution} \hspace{1cm} \text{mg/L} \]

\[ \begin{array}{cccccccc}
\text{Target} & \text{June 2010} & \text{August 2010} & \text{February 2011} & \text{August 2011} & \text{November 2011} & \text{June 2012} & \text{June 2013} & \text{February 2014} & \text{February 2015} \\
\text{Choline cation content, } \text{g dilution} & 0.6 & 0.6 & 0.6 & 0.6 & 0.6 & 0.6 & 0.6 & 0.6 & 0.6 \\
\text{Choline cation content, } \text{mg/L} & 180 & 180 & 180 & 180 & 180 & 180 & 180 & 180 & 180 \\
\end{array} \]
inadequate dietary choline intake and of the PEMT polymorphism rs12325817.

RESULTS

Participants

Recruitment and Random Assignment. Recruitment occurred between April 2012 and September 2014; the last infant was born in January 2015. Sample attrition is detailed in Fig. 1. Seventy participants were randomly assigned to condition—35 to the choline treatment group, 35 to the placebo control group. Among the 70 that were randomized, there were 4 nonstudy-related fetal deaths: 1 spontaneous abortion (placebo), 2 stillbirths (1 choline, 1 placebo), and 1 fetus whose mother was murdered during pregnancy (choline group). In addition, 2 participants who met a priori exclusion criteria were removed from the sample: 1 twin pregnancy identified after randomization (placebo) and 1 very preterm delivery (placebo < 29 weeks of gestation). Voluntary attrition was exceptionally low. One woman (choline group) withdrew immediately after randomization but prior to initiating treatment, and a second participant (choline group) withdrew after delivery but prior to the 6.5-month infant assessments. Data from the woman who withdrew before initiating treatment are not included in this report, leaving a total of 34 participants in the choline group and 35 in the placebo group. Median GA at randomization was 20.1 weeks, range = 8.6 to 26.0.

There were no group differences for weeks GA at time of enrollment for antenatal care, initial maternal screening, or randomization (Table 1). The sample came from an economically disadvantaged, poorly educated population: only 5 mothers in the choline and 4 in the placebo arm had completed high school. The groups did not differ on a broad range of sociodemographic characteristics, including maternal age, SES, education, verbal and nonverbal intellectual competence, stress, and depression. Dietary caloric (energy) intake based on the 24-hour recall interview did not differ between groups, nor did rate of weight gain during pregnancy. Average dietary choline intake on the QFFQ did not differ between groups at randomization or posttreatment and was lower than the 450 mg/d recommended for pregnant women (Institute of Medicine, 2006). There were also no differences on the 24-hour recall interview for the other methyl donor-related nutrients (folate, B12, methionine, lutein) that can impact dietary choline needs, after adjustment for caloric intake, all ps > 0.20.

There were no group differences in alcohol consumption across pregnancy, which was very heavy for both groups at time of conception (≈10.0 standard drinks/occasion on an average of 2 to 3 d/wk). The women in both groups continued to drink heavily across pregnancy (≈8 to 9 drinks/occasion) but reduced their frequency to about 1 to 2 d/wk. They reported concentrating their drinking on the weekends, and binge drinking was common, with 92.6% averaging at least 4 standard drinks/occasion. A majority of the women in both groups met DSM-IV criteria for a diagnosis of alcohol abuse and dependence (American Psychiatric Association, 1994).

Cigarette smoking and illicit drug use during pregnancy did not differ by group. Although smoking was common, number of cigarettes smoked per day was generally light, with 81.4% of smokers reporting < 0.5 pack/d, and only 3.4% reporting at least 1.0 pack (20 cigarettes)/d. None of the women reported using cocaine, heroin, or methaqualone. Marijuana use was reported by 23.5% of the women. Although methamphetamine users were not invited to participate in the study, 4 women recruited as alcohol users later reported also using methamphetamine—2 in the placebo group on a single occasion and 2 in the choline group (1, twice/month; the other, 1 to 2 d/wk). Of the 30 women for whom urine drug tests were available, results were consistent with maternal reports for 25 (83.3%) for marijuana, cocaine, opiates, and methamphetamine. Four of the women reporting marijuana use did not test positive for THC on their urine drug screen. One woman denied all drug use but tested positive for methaqualone. Consistent with the maternal reports, no urine tests were positive for cocaine or opiates.

Adherence. As shown in Fig. 3, adherence (measured as percentage of drink packets used) averaged 68.4% across pregnancy (median = 74.0%; interquartile range = 53.9 to 88.7), and poor adherence (≤ 33.0%) was relatively rare (11.3% of participants). Adherence was excellent (≥ 84%) for 42.0% of the participants and good-to-excellent (≥ 68%) for 58.0%. Mean adherence was slightly, although not significantly, higher in the placebo group, M = 73.5%, compared with 63.0% in the choline group, t = 1.69, p = 0.095. Although older and higher parity women were more adherent, adherence was not related to SES, maternal education, intellectual function, depression, stressful life events, or weight gain during pregnancy (Table 2). Heavier maternal drinking, smoking, and marijuana use during pregnancy were also not associated with poorer adherence, and adherence was good-to-excellent (≥ 68%) for 53.8% of the women with a history of alcohol abuse and dependence, compared with 57.1% of those who did not meet criteria for a DSM-IV diagnosis, χ²(1) = 0.07, p > 0.789. The negative association with methamphetamine use was due primarily to poorer adherence by the 2 frequent methamphetamine users in the sample.

Maternal Plasma Choline Concentration. Group means for plasma choline concentrations collected at randomization and 4 and 12 weeks thereafter are shown in Table 3. The groups did not differ on any of the plasma metabolite concentrations prior to treatment, all ps > 0.20. In a repeated-measures analysis of variance, there was a significant main effect for session; as expected, choline levels increased over time in both groups as the high estrogen state of pregnancy induces endogenous choline production via PEMT (McMahon and Farrell, 1985; Zeisel et al., 1995). There was also a significant interaction for group x treatment
By 4 weeks, plasma choline concentrations were already significantly higher in the choline supplementation than the placebo group, and this group difference continued to be evident at 12 weeks (Fig. 4).

Side Effects. Table 4 presents physical symptoms reported at randomization and aggregated from monthly interviews conducted after treatment began. There were no significant group differences at baseline; twice as many women in the placebo group reported vomiting during the pretreatment period, but this difference was not statistically significant at baseline or during the treatment period. More women randomized to the choline group reported nausea/dyspepsia during the treatment period than in the placebo group (2 vs. 1 d/wk). As indicated earlier, we provided each participant with a monthly supply of crackers to eat with the grape drink because several women did not enjoy drinking it on an empty stomach. Although MAP was slightly lower in the choline group both pretreatment ($t$ (67) = 1.85; $p = 0.069$) and during treatment ($t$ (66) = 1.84; $p = 0.071$), arterial pressure did not change significantly during the course of the trial in either group (choline arm: $t$ (33) = 0.28, $p = 0.783$; placebo: $t$ (33) = 0.44; $p = 0.664$). The groups did not differ on any of the other side effects, and there were no reported study-related serious adverse events in either group. None of the women in the choline group reported a fishy body odor.

A small number of women developed medical problems during pregnancy: 10.1% developed hypertension, 7.2% preeclampsia, and 7.2% syphilis. There were no group differences regarding hypertension (choline 3, placebo 4), preeclampsia (choline 2, placebo 3), or syphilis (choline 3, placebo 3).
placebo), but 4 women in the choline group developed gestational diabetes compared to none in the placebo group, \( \chi^2(1) = 4.37, p = 0.037 \).

**Choline Dietary Intake and Prevalence of the PEMT Variant**

Data from the QFFQs confirmed that none of the women exceeded the UL for choline intake (3.5 g/d). The highest level of dietary choline intake reported in any individual interview was 1.3 g/d; 1.1 and 0.9 g/d were reported in 2 other interviews; and all others were <0.8 g/d. By contrast, 50 (72.5%) women had inadequate dietary choline intake (<450 mg/d) at the pretreatment visit and 59 (85.5%) at the 12-week visit. There was no group difference in number of women with inadequate nonsupplement dietary choline intake averaged across the 3 visits: 31 women (91.2%) in the choline versus 31 (88.6%) in the placebo arm, \( \chi^2(1) = 0.128, p > 0.20 \).

Blood samples from 55 women analyzed for the PEMT polymorphism rs12325817 showed that 12 (21.8%) had at least 1 allele, including 1 (1.8%) who was homozygous for this variant, with no difference between the choline (5 GC, 1 CC) and placebo (6 GC, 0 CC) groups, \( \chi^2(1) = 0.005, p > 0.20 \).

**DISCUSSION**

This study demonstrated the feasibility and acceptability of a maternal choline supplementation regimen in a sample highly disadvantaged, heavy drinking pregnant women in Cape Town, South Africa. Although 8 participants were lost to follow-up due to fetal death or protocol exclusions, only 2 withdrew voluntarily—one immediately after randomization; the other after the birth of her infant—indicating that the protocol was widely acceptable. The success of the random assignment was confirmed by a lack of group differences on any of 18 sociodemographic characteristics.

Adherence was somewhat lower (median = 74%) in this socioeconomically disadvantaged sample than in the 2 U.S. choline supplementation studies of children (82% and 95.7%, in the more middle-class Minnesota [Wozniak et al., 2013] and San Diego [Nguyen et al., 2016] studies, respectively). Hollingshead (2011) SES levels in the San Diego sample averaged 48.5 (small business, professional, or technical), compared with 20.0 (unskilled and semiskilled workers) in our sample, and SES in the Minnesota sample was presumably similar to San Diego, given that the Minnesota participants (children with fetal alcohol spectrum disorders [FASD]) had all been removed from the custody of their biological parents. Adherence is often better in trials with children, whose parents administer treatments, than in adults or adolescents (Ahmed and Aslani, 2013; Tebbi, 1993). In the Ukraine study, in which the assessment of adherence was based on maternal report, all of the choline-treated women reported taking choline on a daily or almost daily basis (Kable et al., 2015). However, the validity of these reports is uncertain given that maternal blood choline levels did not increase in the choline group over the course of that trial (Coles et al., 2015).

The high rate of adherence seen in the Cape Town cohort is impressive when one considers the low SES, poor educational level, and high levels of stress and social disorganization in the communities in which the study participants live. Even for the women with 50% adherence, choline intake from the supplement was substantially higher than the 450 mg/d recommended by the Institute of Medicine (2006). The validity of our packet count measure of adherence was confirmed by the significantly greater increase in plasma

---

**Table 2. Relation of Alcohol and Drug Use and Sociodemographic Characteristics to Protocol Adherence (N = 69)**

<table>
<thead>
<tr>
<th>Sociodemographic characteristics</th>
<th>Protocol adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks gestation at time of randomization</td>
<td>-0.17</td>
</tr>
<tr>
<td>Mother’s age at delivery</td>
<td>0.25*</td>
</tr>
<tr>
<td>Parity</td>
<td>0.31**</td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td>0.10</td>
</tr>
<tr>
<td>Mother’s education (years)</td>
<td>-0.06</td>
</tr>
<tr>
<td>Marital status (married/unmarried)</td>
<td>0.22</td>
</tr>
<tr>
<td>Peabody Picture Vocabulary Test</td>
<td>0.06</td>
</tr>
<tr>
<td>Raven Progressive Matrices score</td>
<td>0.10</td>
</tr>
<tr>
<td>Beck Depression Inventory score</td>
<td>0.13</td>
</tr>
<tr>
<td>Stressful Life Events (number of events)</td>
<td>0.16</td>
</tr>
<tr>
<td>Perceived stress</td>
<td>0.07</td>
</tr>
<tr>
<td>Daily caloric intake (KJ/d)</td>
<td>-0.07</td>
</tr>
<tr>
<td>Rate of pregnancy weight gain (kg/wk)</td>
<td>-0.02</td>
</tr>
<tr>
<td>History of alcohol abuse and/or dependence</td>
<td>0.01</td>
</tr>
<tr>
<td>Alcohol and drug use during pregnancy</td>
<td></td>
</tr>
<tr>
<td>Absolute alcohol (AA) per day at conception</td>
<td>0.16</td>
</tr>
<tr>
<td>Drinks/occasion at conception</td>
<td>0.20</td>
</tr>
<tr>
<td>Frequency of drinking at conception (d/wk)</td>
<td>0.08</td>
</tr>
<tr>
<td>AA per day across pregnancy</td>
<td>0.07</td>
</tr>
<tr>
<td>Drinks/occasion across pregnancy</td>
<td>0.11</td>
</tr>
<tr>
<td>Frequency of drinking across pregnancy (d/wk)</td>
<td>-0.02</td>
</tr>
<tr>
<td>Cigarettes per day during pregnancy</td>
<td>0.01</td>
</tr>
<tr>
<td>Marijuana during pregnancy (d/mo)</td>
<td>-0.15</td>
</tr>
<tr>
<td>Methamphetamine during pregnancy (d/mo)</td>
<td>-0.30*</td>
</tr>
</tbody>
</table>

\(*p < 0.10, *p < 0.05, **p < 0.01.\)

Values are Pearson r.

---

**Fig. 3.** Participant adherence to the study protocol.
Table 3. Choline and Choline-Related Metabolite Concentrations by Treatment Arm

<table>
<thead>
<tr>
<th></th>
<th>Choline (µM)</th>
<th>Placebo (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>M ± SD</td>
</tr>
<tr>
<td>Choline (µM)a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreatment</td>
<td>29</td>
<td>8.7 ± 2.5</td>
</tr>
<tr>
<td>4 weeks</td>
<td>31</td>
<td>10.7 ± 4.2</td>
</tr>
<tr>
<td>12 weeks</td>
<td>29</td>
<td>14.4 ± 11.5</td>
</tr>
<tr>
<td>Betaine (µM)b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreatment</td>
<td>29</td>
<td>20.3 ± 6.2</td>
</tr>
<tr>
<td>4 weeks</td>
<td>31</td>
<td>21.8 ± 8.8</td>
</tr>
<tr>
<td>12 weeks</td>
<td>29</td>
<td>20.1 ± 9.4</td>
</tr>
<tr>
<td>Phosphatidylcholine (µM)c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreatment</td>
<td>29</td>
<td>2178.2 ± 295.8</td>
</tr>
<tr>
<td>4 weeks</td>
<td>31</td>
<td>2319.5 ± 327.0</td>
</tr>
<tr>
<td>12 weeks</td>
<td>29</td>
<td>2452.3 ± 301.0</td>
</tr>
<tr>
<td>Sphingomyelin (µM)d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreatment</td>
<td>29</td>
<td>608.9 ± 102.7</td>
</tr>
<tr>
<td>4 weeks</td>
<td>31</td>
<td>600.0 ± 99.8</td>
</tr>
<tr>
<td>12 weeks</td>
<td>29</td>
<td>664.4 ± 138.4</td>
</tr>
</tbody>
</table>

aGLM for choline:  
Group (choline/placebo): f(66) = 2.78, p = 0.007  
Session (pretreatment/posttreatment), f(105) = 5.10, p < 0.0001  
Group by session interaction, f(105) = 3.36, p = 0.001  
bGLM for betaine:  
Group (choline/placebo): f(66) = 3.83, p = 0.0003  
Session (pretreatment/posttreatment), f(105) = 0.08, p = 0.938  
Group by session interaction, f(105) = 0.37, p = 0.712  
cGLM for phosphatidylcholine:  
Group (choline/placebo): f(66) = 0.96, p = 0.342  
Session (pretreatment/posttreatment), f(105) = 2.53, p = 0.013  
Group by session interaction, f(105) = 0.88, p = 0.495  
dGLM for sphingomyelin:  
Group (choline/placebo): f(66) = 0.50, p = 0.621  
Session (pretreatment/posttreatment), f(105) = 1.13, p = 0.261  
Group by session interaction, f(105) = 0.65, p = 0.519

Blood samples missing for 10 women at baseline (1 spontaneous abortion, 1 insufficient blood, 8 sample handling problems); 10, at 4 weeks (in addition to 1 spontaneous abortion missing at baseline: 1 pregnant participant murdered, 1 multiple birth, 6 insufficient blood, 1 sample handling); and 15, at 12 weeks (in addition to 1 spontaneous abortion missing at baseline and 1 pregnant participant murdered and 1 multiple birth missing at 4 weeks: 1 very preterm birth, 3 insufficient blood, 3 sample handling, 5 delivered prior to final laboratory visit).

Adherence was poor for the 2 women who initiated regular methamphetamine use during the trial. Good adherence was not dependent on higher levels of maternal education or intellectual function, lower levels of depression or stressful life events, or more optimal nutritional status. The only significant predictors of better adherence were higher parity and older maternal age. Adherence was poor for the 2 women who initiated regular methamphetamine use during the trial.

The choline dose administered in this trial (2 g/d) is considerably higher than in the previous human FASD choline supplementation studies (range = 500 to 750 mg/d). As detailed above, total daily intake for all participants was still well below the UL for choline (3.5 g/d) established by the IOM. Low blood pressure, the side effect that provided the LOAEL on which the UL was based, was not found in either group. Fishy body odor was not reported by any participant. This odor, which was reported in a high proportion of the choline-treated children in the Wozniak and colleagues (2013) study, results from accumulation of trimethylamine, a compound that is formed when choline transporters in the small intestine are saturated and excess choline reaches bacteria in the gut, accumulating in sweat and urine (Zeisel et al., 1989). As recommended by SHZ, we instructed the participants to split the choline dose, ingesting the contents of 1 drink packet in the morning and 1 in the evening, thereby reducing trimethylamine formation. The only side effect reported to increase in the choline-treated women during the trial was nausea/dyspepsia, which in many cases appeared to result from ingesting the fizzy grape drink on any empty stomach. This effect did not appear to be clinically significant, however, as the groups did not differ on daily caloric intake or rate of weight gain during pregnancy. Although the incidence of gestational diabetes was higher in the choline group, gestational diabetes is not a known effect of choline, and there was only a minimal amount of sugar (2.5 g/d) in the choline supplement. Future larger studies are needed to determine whether this was, in fact, the result of...
supplementation or a type I error in light of the large number of outcomes examined here.

Mean dietary choline intake for this sample (364.5 mg/d) was remarkably similar to that seen in a U.S. sample of pregnant women in California (392.9 mg/d; Shaw et al., 2004). The finding that the means in both these samples were substantially below the Institute of Medicine (2006) 450 mg/d criterion for adequate dietary intake suggests that a maternal choline supplementation intervention may be particularly effective in both these populations (Zeisel, 2011). By contrast, the prevalence of the rs12325817 allele of the choline-metabolizing enzyme PEMT was substantially lower (21.8%) than in the U.S. sample studied in North Carolina (72%). Silver and colleagues (2015) have reported that the prevalence of this SNP is also low in people of West African (The Gambia) ancestry and hypothesized that traditional diets low in choline negatively select against this polymorphism. From a statistical analysis perspective, it would be preferable to have approximately equal numbers of high- and low-risk participants within each group (e.g., adequate vs. inadequate dietary intake) to test the hypotheses that inadequate dietary intake and/or the presence of a PEMT allele may modify the efficacy of the maternal supplementation intervention. The very high incidence of dietary inadequacy and relatively low incidence of the PEMT allele in this sample will make it difficult to test the hypothesis that maternal choline supplementation during pregnancy is likely to be more effective in cases where insufficient choline is available to the fetus.

Limitations

Given that the sample size was small, there is a need to assess the degree to which this intervention will be scalable when administered to a larger confirmatory sample. This trial was conducted in the Cape Coloured community because the unusually high prevalence of heavy drinking during pregnancy made it possible to assess the feasibility and acceptability of this nutritional intervention in a more time-efficient and cost-effective manner than would be possible in the United States. Future studies are needed to confirm its acceptability in other populations.

CONCLUSIONS

These data demonstrate that a choline supplementation program with very heavy drinkers during pregnancy is feasible even among highly disadvantaged, poorly educated women and in a cross-cultural setting. The acceptability of this intervention is indicated by impressive adherence to a twice-daily maternal nutritional supplementation protocol and our finding that adherence was not related to maternal education, intellectual function, depression, stressful life events, nutritional status, or alcohol use. One strength of this study was that all participants initiated the trial prior to end of the second trimester, with half (49.3%) initiating treatment by the middle of the second trimester. Data from the few studies that have compared the efficacy of choline supplementation in rats earlier (e.g., during the equivalent of the second trimester in humans) versus later during development suggest that supplementation earlier in development may be more effective. The unusually high prevalence of heavy maternal drinking and FAS in Cape Town made it an appropriate setting to assess the feasibility and efficacy of a nutritional supplementation intervention for FASD.

ACKNOWLEDGMENTS

We thank the members of the Data Safety Monitoring Board: Sydney Hans, PhD (Chair), a developmental psychologist with expertise in assessment of long-term effects of teratogenic exposures, University of Chicago; Marylou Behnke, MD, a neonatologist with expertise on teratogenic exposures, University of Florida; Judette Louis, MD, MPH, an obstetrician with expertise in fetal alcohol-related pregnancy complications, Case Western Reserve University; and Cynthia Arfken, PhD, a statistician with expertise in...
alcohol abuse research, Wayne State University. We thank Kristine Lukasik, Balchem Corporation, New Hampton, NY, who conducted the regular quality control analyses for the choline supplement; Rocco Anzaldi, RPh, a senior research pharmacist at Children’s Hospital Boston, who supervised the construction of the randomization list and the labeling and shipment of the choline packets to UCT, and Wynand Smythe, PhD, BPharm., Division of Clinical Pharmacology, UCT, who retained the randomization list in case of an adverse medical event including spontaneous abortion, miscarriage, or stillbirths requiring unblinding for review by the Data Safety Monitoring Review Board. We thank Lori Bechard, PhD, RD, Sharmilah Booley, MSc, and Baheya Najaar, MSc, who worked on the development of the quantitative choline food frequency questionnaire with MSS, as well as Monika Uys, PhD, Catherine Day, RD, and Nicola Cooper, the dieticians who administered 24-hour recall interviews that were processed by Dr. Bechard. We thank our research nurses Maggie September, Patricia O’Leary, and Beverly Arendse, and our project driver Patricia Solomon for their work recruiting the cohort and conducting home visits involving adherence monitoring during the intervention. We are also extremely grateful to the mothers for their participation in this supplementation trial.

FUNDING
Grants from the NIH/National Institute on Alcohol Abuse and Alcoholism R21AA020332 (to SWJ), R01AA016781 (to RCC), K23AA020516 (to RCC), and 2P30DK040561 (to CPD); National Institute of Diabetes and Digestive and Kidney Diseases R01DK115380 and 2P30DK040561 (to CPD); National Institute of Diabetes, R01AA016781 (to SWJ), K23AA020516 (to RCC), and Abuse and Alcoholism R21AA020332 (to SWJ),

CONFLICT OF INTEREST
The authors declare no competing financial interests.

REFERENCES


Meck WH, Smith RA, Williams CL (1989) Organizational changes in cholinergic activity and enhanced visuospatial memory as a function of choline administered prenatally or postnatally or both. Behav Neurosci 103:1234–1241.


